title: The effect of dihomogammalinolenic acid on platelet aggregation and prostaglandin release, erythrocyte membrane fatty acids and serum lipids: evidence for defects in PGE1 synthesis and delta 5-desaturase activity in insulin-dependent diabetics.
abstract: The effect of dihomogammalinolenic acid (DHLA) administration on platelet aggregation and prostaglandin production, erythrocyte fatty acid composition and serum lipids was compared in healthy subjects and insulin-dependent diabetics (IDDs). In healthy subjects, DHLA caused a significant inhibition of ADP-induced platelet aggregation and an increase in platelet PGE1 release; IDDs did not show these changes. There were no differences, however, in platelet thromboxane A2 (TXA2) or PGE2 release between healthy subjects and IDDs before and after DHLA. Following DHLA, the arachidonic acid content of erythrocytes increased in healthy subjects; this increase was not observed in IDDs. DHLA induced a significant fall in serum non-esterified fatty acid concentrations in both groups without altering either cholesterol or triglyceride concentrations. These data show for the first time that IDD platelets may have a specific defect of PGE1 synthesis quite distinct from the delta 5- and delta 6-desaturase defects known to be associated with experimental diabetes; this defect may contribute to platelet hyper-aggregability in diabetes; and DHLA has a potent antilipolytic effect in vivo; and erythrocytes from IDDs may have a delta 6-desaturase defect.
mesh_terms: D015126:8,11,14-Eicosatrienoic Acid / Q000494:pharmacology*; D000328:Adult; D000527:Alprostadil / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D000090943:Delta-5 Fatty Acid Desaturase; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000201:enzymology; D015232:Dinoprostone; D004910:Erythrocyte Membrane / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism*; D044943:Fatty Acid Desaturases / Q000378:metabolism; D005227:Fatty Acids / Q000097:blood*; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000097:blood / Q000494:pharmacology*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010978:Platelet Factor 4 / Q000032:analysis; D011453:Prostaglandins / Q000097:blood*; D011458:Prostaglandins E / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood; D014280:Triglycerides / Q000097:blood; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D015126:8,11,14-Eicosatrienoic Acid; D000527:Alprostadil; D001786:Blood Glucose; D002784:Cholesterol; D000090943:Delta-5 Fatty Acid Desaturase; D015232:Dinoprostone; D044943:Fatty Acid Desaturases; D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D005231:Fatty Acids, Unsaturated; D006442:Glycated Hemoglobin; D008055:Lipids; D010978:Platelet Factor 4; D011453:Prostaglandins; D011458:Prostaglandins E; D013929:Thromboxane B2; D014280:Triglycerides; D001620:beta-Thromboglobulin